Clinical Network Services (UK) Ltd
Clinical Network Services (CNS) is an integrated service group focused on product development, headquartered in Australia with offices in New Zealand, the UK and the USA, who create value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.
Amelia BesharaSenior Business Development Manager
Clinical Practice Research Datalink (CPRD)
CPRD is the leading global provider of real-world retrospective and prospective research services based on representative UK population electronic health data. Our services are used from discovery to post-marketing authorisation by academia, industry and governments worldwide to drive real world evidence in public health research.
CPRD is a centre of the Medicines and Healthcare products Regulatory Agency.
Temis VasiliBusiness Development Manager
Curileum Discovery Ltd
Curileum is a discovery stage company in London targeting defective mucosal stem cells that underpin serious gastrointestinal (GI) diseases and disorders with major GI complications.
Jeffrey MooreFounder & CEO
Drug Discovery & Development Consultants Ltd
3DConsultants provide scientific consultancy, due diligence services and project management as well as support in helping you to start or sell your company.
Our business model is based upon the partnership’s capability of providing a specialist solution for those looking for expert advice and support across all aspects of the small molecule drug discovery and development process. We are able to achieve this through deploying a team of highly experienced scientists with core competencies across a broad range of disciplines including in vitro/in vivo biology, medicinal chemistry, structural biology/CADD, AI, DMPK, pre-clinical development (CMC, tox, scale-up) and early clinical development operations.
With more than a hundred years of experience in both biotech and pharma across the discovery and development spectrum, our team has the skill sets and experience to provide practical, cost-efficient and timely solutions to your project through consultation on an individual basis or as a team.
Please contact us to discuss how we can best meet your needs.
Health and Care Research Wales
Exhibiting at Booth 8
Health and Care Research Wales is a Wales wide organisation funded and overseen by the Welsh Government’s Research and Development Division.
The aim of Health and Care Research Wales is to increase the amount of high quality research and development that takes place in NHS Wales.
Health and Care Research Wales provides infrastructure and funding to support and increase capacity for Research and Development within NHS Wales.
We provide a number of key services to industry so that research in Wales can be setup and delivered in a streamlined and efficient way:
-Early feedback on commercial projects/studies
-Wales-wide feasibility service (which links in with the UK wide site identification service)
-Study setup and oversight support
-Support with Investigator engagement
-Support with contract and costing negotiations (using a 'once for Wales 'approach to setup of multi-site studies in NHS Wales).
-Health and Care Research Wales also run a range of research funding schemes and manage the NHS R&D funding allocation which is provided to Health Boards and Trusts in Wales to increase clinical research activity.
Matthew HarrisCluster Lead
Rachel NelsonIndustry Research Coordinator
Health Innovation Research Alliance Northern Ireland (HIRANI)
The Health Innovation Research Alliance Northern Ireland (HIRANI) was established in 2019 as an alliance between Queen’s University Belfast, Ulster University, The Department of Health, The Department for the Economy and Industry. The objectives for HIRANI are to provide a single point of contact for external collaborators to be able to understand areas of research and innovation excellence in Northern Ireland with a view to collaboration and investment. In addition, HIRANI will drive increased collaboration and research coordination within the health and life science community within Northern Ireland.
HIRANI has a bold ambition to bring together the component strengths within Northern Ireland, provide leadership and focus and as a result drive prosperity and improve patient outcomes within the region.
IDACO Consulting Limited
IDACO Consulting Limited
IDACO Consulting Limited is a solution-oriented consultancy with a specific focus on supporting companies in the Pharmaceutical, Biotechnology, Medical Device, Life Science and Healthcare sectors.
The IDACO Team bring together pre-clinical and clinical expertise, along with an extensive network of academic, outsourcing and commercial contacts, to support the development and commercialisation of bio-pharmaceutical products and medical devices.
IDACO Consulting also has the capabilities to undertake projects involving healthcare including the optimisation of healthcare services.
ImmuPharma PLC is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM). The company is focusing on developing novel medicines for specialist indications with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and over 70 patents. Forigerimod (P140 or Lupuzor™) is the company’s most advanced drug candidate for autoimmune diseases and is an immunomodulator, not an immunosuppressant. Lupuzor ™ received "Fast Track" designation from the US FDA and has recently completed a Phase III trial.
Forigerimod is a first-in-class peptide drug modulating autophagy.
ImmuPharma is based in London, U.K. and has three subsidiaries in France and one in Switzerland.
Dimitri DimitriouChief Executive Officer
- Licensing and product Development
- Spin out from UCL School of Pharmacy based on 20+ years research from laboratory of Prof. Abdul Basit
- Experts in oral drug delivery, range of licensable technologies for targeted delivery in GI tract
- Unique GI models that provide expert analysis of formulation behaviour under physiologically appropriate conditions
Karma Oncology is a specialist oncology clinical development company headquartered in Scotland with offices in Ireland, Netherlands and USA. We offer a complete range of development services from clinical development planning, protocol design and authoring, strategic country/site selection, regulatory submissions, through to clinical trial execution and reporting.
With Karma, experience makes the difference - Our team has successfully completed programs in a broad range of solid tumour and hematologic indications utilizing an array of different therapeutic approaches including immunotherapy and autologous cell therapy and CAR-T cell therapy.
Karma is flexible - We can provide selected individual services, and extend to full-service global CRO capabilities as the program needs expand. Our size allows us to be flexible, innovative and responsive to individual sponsor requirements and to adhere strictly to specified development timelines.
Karma is different - Our Project Managers have extensive oncology experience, our monitors are professional, mature 'career' CRAs - not trainees - and we have the lowest staff turnover in the industry (<5%). Many of our staff come from a nursing or medical background, and for international studies we use CRAs native to their country.